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During public health emergencies and disease outbreaks such as 
the COVID-19 pandemic, there is a moral and ethical obligation to 
conduct research. Research may help in better understanding the 
mechanisms and epidemiology of disease, population dynamics, 
optimal therapeutic approaches, protection for those who are most 
vulnerable, and prevention of future outbreaks.[1] A key pillar of 
research is informed consent, which should be paramount in the 
conduct of COVID-19 research. Yet seeking informed consent may 
be difficult, particularly if the outbreak reaches that phase of the 
pandemic at which demand exceeds available resources (including 
personal protective equipment, medication, intensive care beds, 
ventilators and specialised equipment, and healthcare workers to 
use and operate them). Researchers’ ability to seek informed consent 
may also be compromised by pandemic-mitigating measures such as 
lockdown and physical distancing policies, and by the nature of the 
patient’s illness. Taken together, there may be circumstances in which 
the consent that is sought is imperfect.
Valid informed consent is consent that is informed, given 
voluntarily by a competent person.[2] To achieve this type of consent, 
one would normally expect the consent process to be conducted 
without time pressure, in a calm and confidential environment, 
where a prospective participant is able to ask questions and is given 
time to consider the request for participation. During the COVID-19 
pandemic, several or all of these conditions may be compromised. 
For instance, if hospitals are overwhelmed by COVID-19 patients, 
it may not be possible to conduct informed consent processes in a 
calm and confidential environment. Similarly, physical distancing 
requirements may mean that consent processes are performed 
telephonically or electronically.
Internationally, the recognition that consent for COVID-19 
research may be imperfect has led to a range of suggestions for 
ensuring that research remains ethical. For instance, some regulators 
have allowed certain kinds of research – such as research involving 
patient data – to be conducted without consent.[3] In other cases, 
there have been adaptations in the way in which informed consent 
is obtained. In this article, we describe international guidance and 
suggest a local approach to informed consent that continues to 
respect the autonomy of vulnerable participants while also enabling 
research that has social value.
International guidance for informed 
consent during epidemics
Following the 2002 - 2004 severe acute respiratory syndrome (SARS) 
and 2014 - 2016 Ebola outbreaks, several international initiatives 
focused on developing ethics guidance for research conducted during 
public health emergencies.[1,4,5] There is also additional guidance for 
research conducted on participants with COVID-19.[6-8] Together, 
these documents endorse, as a first principle, that informed consent is 
required for research participation in epidemics in all but exceptional 
circumstances. The way in which informed consent is collected 
during outbreaks must be aligned with how informed consent 
is collected in normal (non-emergency) times. The argument is 
predicated on the view that urgency of the moment does not justify 
eroding standards of ethical research conduct. However, as a second 
principle, these documents recognise that practical and ethical 
considerations relating to the particular circumstances may mean 
that the consent process requires ‘adaptation’.[9]
Adapting the consent process:  
Proxy, delayed and waived consent
Deliberations on informed consent adaptations during COVID-19 
must include consideration from whom consent is sought, when 
consent is obtained, whether it is obtained at all, and how it is 
obtained.
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Regarding when consent is obtained, researchers should explore with 
research ethics committees (RECs) the use of delayed (or deferred) 
consent, commonly used where research involves participants who 
may be temporarily incapacitated but are likely to recover, and where 
obtaining research samples and data is time-sensitive.[10,11] This may 
be the case in persons with severe COVID-19 who are likely to 
recover. Where a delayed consent model is used, arrangements need 
to be made for individuals to be contacted at a later stage to secure 
their retrospective approval for ongoing research participation and/
or sample and data storage for future use.[4]
Considering who consent is obtained from, in cases where capacity 
to give informed consent is compromised, researchers should consider 
proxy consent. Proxy consent is consent from a person’s next of 
kin before the start of research procedures, and is often used where 
research involves people with reduced capacity to consent where 
their inclusion is ethically justifiable and there is either a favourable 
risk-to-benefit ratio or a favourable risk-to-generalisable knowledge 
ratio, where benefits or generalisable knowledge outweigh potential 
harms.[12,13] Where no statutory proxy is available, the National Health 
Act No. 61 of 2003[14] specifies the sequence of legally appropriate 
treatment proxies as the spouse or partner, parent, grandparent, adult 
child, brother or sister. Always, the ‘best interest’ principle should be 
upheld – research should only be conducted where participation is 
not contrary to the individual’s best interest. Once capacity is regained, 
the participant should provide delayed consent for ongoing research 
participation and/or the storage and future use of samples and data.
With regard to whether consent is obtained at all, there may be 
certain instances in which RECs may be approached for a waiver 
of informed consent.[15] RECs may approve such a request, for 
instance where research involves retrospective record review, or the 
proposed use of anonymised data or samples stored in a repository 
created for non-research purposes. RECs may approve a waiver 
of consent for secondary use of data or samples if the research 
involves no more than minimal risk of harm, if the waiver would not 
adversely affect participants’ rights and welfare, and if the research 
could not practically be carried out without the waiver.[9] Where a 
waiver of informed consent is sought from an REC, the justification 
provided needs to be aligned with normal considerations during 
non-emergency times, including whether the risk is considered 
acceptable, that the research has social value for the community 
involved, and an explanation that the research cannot be done in any 
other way, or with other participants.
In terms of how consent is obtained, suggested adaptations include 
consideration of the kinds of information that are provided, how or 
when the proposed study is explained to participants, and how and 
when consent is recorded. COVID-19-specific recommendations 
include increased use of electronic and telephonic means to explain 
studies and/or capture consent, often in the presence of an impartial 
witness.[6,7]
Proposed consent decision flowchart
Drawing on available guidance and considering the South African 
(SA) research environment, we propose a blended approach to 
informed consent for COVID-19 research that combines the range of 
consent models described above (Fig. 1). We propose that researchers 
always seek individual informed consent from patients who have the 
capacity to consent and where this is practically possible (considering 
research staff availability and risk of contamination). Where the 
patient lacks capacity to consent, researchers should seek remote 
telephonic or electronic proxy consent from the patient’s next of kin, 
combined with delayed consent from patients who recover. If the 
patient dies, we propose that unless permission to remove samples 
and data was included in a person’s will, researchers should first 
seek proxy consent from ‘the spouse, partner, major child, parent, 
guardian, major brother or major sister of that person in the specific 
order mentioned’ (section 62(2) of the National Health Act).[14] 
Where no proxy consent can be obtained, RECs may be approached 
to consider a waiver of informed consent for obtaining samples from 
a deceased patient, on a case-by-case basis.[16]
Practical considerations for seeking 
informed consent
Distinction between COVID-19 severe disease and 
competence to consent
COVID-19 affects more than patients’ physical functioning: it may also 
affect their emotional, social and occupational functioning, as well as 
their competence to give informed consent. Objective clinical indicators 
are not enough to assess the overall effect of disease on competence. 
The conceptual boundaries between symptoms, disease severity, and 
health-related quality of life and competence are frequently blurred in 
practice. In all cases, an evaluation of an individual’s cognitive abilities 
and understanding needs to be undertaken, regardless of the severity 
of illness. In other words, severely ill patients may still be able to give 
informed consent, and research staff should assess whether patients 
presenting with COVID-19 are able to understand the information 
provided and have the capacity to consent, as well as the ability to 
communicate their decision.
People seeking informed consent
During times of lockdown or in situations where individuals are 
encouraged to practise physical distancing, it may not be possible or 
desirable for research staff to be present at the research site. At the 
same time, it would be undesirable to rely on healthcare workers to 
conduct consent processes, particularly when the pandemic reaches 
‘crisis’ proportions. Where it is not possible for research staff to 
personally seek informed consent, it may be possible to rely on 
healthcare workers to take on this task if there is spare capacity in 
the facility where the research is conducted. At no time may seeking 
informed consent undermine or endanger the quality of healthcare 
provided to the patients. Therefore, in situations where (i) it is not 
legal or safe for research staff to collect informed consent in person, 
and (ii) there are no spare healthcare staff available to seek informed 
consent, we suggest that researchers, where possible, seek telephonic 
or electronic consent from the patient, but that these be accompanied 
by more vigorous assessment of capacity to provide consent – in both 
written and alternative formats.
Recording informed consent
A challenge during the COVID-19 crisis is that the virus is highly 
contagious, so that there is not only a risk to the persons seeking 
consent, but also that the materials on which consent is recorded 
could be contaminated. This may apply not only to paper documents 
used to capture signatures, but also to any audio or video equipment 
used to record consent, such as mobile phones or voice recorders. 
These materials must be considered a biohazard, and measures 
should be put in place to safeguard the wellbeing of research staff and 
those who process and store samples. A range of alternatives have 
been proposed to deal with this challenge. For instance, the Food and 
Drug Administration in the USA has formally endorsed telephonic 
and electronic consent as an alternative to paper-based consent, 
provided that it is accompanied by efforts to seek delayed consent 
post-emergency.[7] The European Commission has adopted witnessed 
verbal consent, duly recorded, as an acceptable alternative.[17] Among 
these suggestions, what stands out is the importance of ensuring 
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transparency and accountability, for detailing the various decisions 
made and for indicating how consent was obtained.
The ‘ethics ecosystem’ of research 
during emergencies
When designing a consent process for COVID-19 research, it is 
imperative to consider that informed consent is not the only way 
to ensure that people are treated as moral equals.[5] Where the 
consent process is imperfect, other elements of the ethics ecosystem 
of research need to be strengthened to ensure that the individual’s 
moral agency is respected. Generally, three components of this 
ecosystem are identified, namely research ethics review, community 
engagement, and arrangements for the future use of samples and data.
Research ethics review
Robust scientific and REC review, albeit rapid, of proposed research 
studies is arguably even more important during times of crisis, 
particularly in situations where informed consent may be imperfect. 
As emphasised previously, the urgency of generating knowledge that 
could help address the pandemic is no justification for conducting 
research that is unethical, and RECs need to be extra vigilant to 
ensure that processes and procedures are acceptable and fair. This 
may involve ensuring that only research that has ‘social value’[18] is 
acceptable. RECs need to be vigilant to ensure that, in cases where 
consent processes are less than ideal, researchers have strengthened 
other elements of research protection, including provisions for 
community engagement and comprehensive descriptions of whether 
samples and data will be retained for future use, how they will be 
shared, and whether there are any restrictions on future use.
Community and public engagement
A second key component of research that needs to be strengthened 
if consent may be imperfect is community and public engagement, 
which enable transparency, preventing an ‘avoidance of information 
disclosure requirements’ codified in the consent process.[19] Examples 
include presenting information on social media and conventional 
media such as local radio stations, newspapers and television 
broadcasts, especially in cases where in-person contact is not 
permissible. Where permissible, researchers should draw on existing 
engagement activities, seeking feedback on: (i) study rationale and 
Does the patient have capacity* to 
provide valid informed consent?
Can consent be recorded 
without risk of contamination 
of sta or materials? 
Obtain contact details 
of next of kin‡
Seek written informed 
consent from the patient 
for research participation
Seek alternative form of consent 
(e.g. telephonic, electronic) from the 
patient for research participation
Are next of kin contactable by remote 
means (telephonically or electronically), 
following reasonable eorts to contact all 
potential proxy decision-makers for the patient?
Where possible, seek assent from 
the patient for research participation. 
Refusal or resistance to participation 
indicated by words or behaviour, 
takes precedence over proxy consent
Seek a possible waiver 
of informed consent 
from the REC on a
case-by-case basis
Seek proxy consent (telephonic 
or electronic) for the patient’s 
research participation
Does the patient survive?
Seek delayed consent for the patient’s 
continued research participation 
(in written or alternative form)
Seek proxy consent§ for the continued 
use of the deceased patient’s data 
and samples for research
If next of kin are not contactable 
following reasonable eorts 
to contact all proxies, seek a possible 
waiver of informed consent from 





Fig. 1. Example of a flowchart for consent process for COVID-19 research. (REC = research ethics committee. *It is important to determine whether the patient 
has both the capacity to decide whether to participate and the ability to communicate that decision.[9] For example, unconscious or severely ill patients would 
probably not have capacity to provide informed consent. Patients who are on ventilators may have capacity to give informed consent, but may not be able to 
communicate their decision. COVID-19 patients who are not in the intensive care unit would probably be able to provide informed consent. †Adults who are 
incapacitated should only take part in research when their participation is indispensable to the research, and a strong ethical justification must be provided 
for their proposed inclusion.[9] ‡Where no statutory proxy is available, but the ratio of risk of harm to benefit or generalisable knowledge justifies research 
participation, proxy consent may be ethically permissible. The National Health Act No. 61 of 2003[14] (section 7) specifies the sequence of legally appropriate 
treatment proxies as spouse or partner; parent; grandparent; adult child; brother or sister. §If no provision for research was made in the patient’s will, proxy 
consent for the use of data and samples from a deceased individual should be obtained from ‘the spouse, partner, major child, parent, guardian, major brother 
or major sister of that person in the specific order mentioned’ (section 62(2) of the National Health Act).[14] Note that the order of decision-makers in the Act 
is slightly different when the patient is alive compared with when the patient is deceased. 
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recruitment procedures; (ii) the proposed consent process, including 
proposals to deviate from gold standards or seek waivers for consent; 
and (iii) any other ethical considerations pertinent to the proposed 
research. Post-research, it is imperative that researchers communicate 
their study findings.
Future use of samples and data
Finally, where researchers intend to retain samples and data for future 
use and where the consent process was imperfect, RECs need to decide 
on the kinds of research these resources could be used for. In cases 
where adaptations to the consent process were justified by the urgency 
of the pandemic, it may be inappropriate to use resources for research 
that is unrelated to the pandemic. For instance, it would be unethical 
to use samples collected during the COVID-19 pandemic for broad 
population genomic studies or to interrogate questions completely 
unrelated to this condition. In line with current practice, researchers 
should outline plans and justifications for storage, sharing and future 
use in their application to the REC, and these need to be proportionate 
and justifiable, considering limitations of the consent process.
Conclusions
In SA, the right to give informed consent before participation in 
research is entrenched in the Constitution, and remains central to 
the conduct of research on COVID-19. In this article, we outline key 
principles for consideration in the design of consent processes for 
such research (Table 1). As far as possible, duly recorded individual 
informed consent will need to be collected before participants are 
enrolled in COVID-19 research, particularly when the research 
enrols healthy persons or where the pressures on the healthcare 
system are still manageable. If necessary, the consent process may 
need to be adapted for practical or safety concerns. This could 
mean turning to telephonic or electronic means to collect informed 
consent. Only in extraordinary circumstances – for instance, when 
patients’ competence is compromised – may researchers consider 
proxy consent from next of kin for the collection of samples, with 
delayed consent being obtained from participants who survive. 
Seeking a waiver of informed consent is a last resort and needs to be 
fully justified to the research ethics committee. Where the consent 
process is compromised, other elements of the ethics ecosystem for 
research need to be strengthened. This includes strengthening rapid 
ethics review, ensuring broad communication about the study, and 
describing the limits on the future use of samples and data.
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